Spyre Therapeutics' CEO Sells 15,000 Shares [Yahoo! Finance]
Spyre Therapeutics, Inc. (SYRE)
Company Research
Source: Yahoo! Finance
His transactions reduced his direct ownership to 671,907 shares. These 10 stocks could mint the next wave of millionaires › This biotech innovator in antibody therapies for inflammatory bowel disease reported a notable insider sale, according to a new SEC filing. Cameron Turtle, Chief Executive Officer of Spyre Therapeutics (NASDAQ:SYRE) , directly sold 15,000 shares in open-market transactions on Jan. 2, for a total consideration of more than $460,000 according to a SEC Form 4 filing Metric Value Shares sold (direct) Transaction value ~$460,134 Post-transaction shares (direct) Post-transaction value (direct ownership) ~$20.5 million Transaction value based on SEC Form 4 weighted average purchase price ($30.68); post-transaction value based on Jan. 2, 2026 market close ($30.58). How significant was the transaction relative to Cameron Turtle's total direct holdings? The 15,000-share sale accounted for 2.2% of direct ownership/ Were any indirect entities o
Show less
Read more
Impact Snapshot
Event Time:
SYRE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SYRE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SYRE alerts
High impacting Spyre Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SYRE
News
- Spyre Therapeutics (NASDAQ:SYRE) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $70.00 price target on the stock.MarketBeat
- Wall Street Bullish on Spyre Therapeutics, Inc. (SYRE) with Strong Buy Rating [Yahoo! Finance]Yahoo! Finance
- Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2 [Yahoo! Finance]Yahoo! Finance
- Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2GlobeNewswire
- Spyre Therapeutics Announces Grants of Inducement AwardsGlobeNewswire
SYRE
Earnings
- 11/4/25 - Beat
SYRE
Sec Filings
- 1/13/26 - Form 4
- 1/13/26 - Form 4
- 1/13/26 - Form 4
- SYRE's page on the SEC website